Ivabradina Aurobindo

Active Ingredient:: Ivabradine Hydrochloride
Origin:: EU

Ivabradina Aurobindo (Ivabradine Hydrochloride)

Q: What conditions is Ivabradina Aurobindo used to treat?

Ivabradina Aurobindo is prescribed to lower heart rate in patients with chronic stable angina pectoris and in those with heart failure that has a reduced ejection fraction. By slowing the sinus node, it helps relieve angina symptoms and may improve functional capacity in heart‑failure patients.

Q: How does Ivabradine Hydrochloride work in the body?

Ivabradine Hydrochloride selectively blocks the funny (If) current in the sinoatrial node. This current normally drives spontaneous depolarisation of pacemaker cells. Inhibition slows the heart’s intrinsic pacing, producing a controlled reduction in heart rate without decreasing myocardial contractility or blood pressure.

Q: What is the usual dose of Ivabradina Aurobindo?

The dose of Ivabradina Aurobindo is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerability. Dosage adjustments are made during treatment to achieve the target heart‑rate range while monitoring for adverse effects.

Q: Is Ivabradina Aurobindo safe during pregnancy or breastfeeding?

The safety of Ivabradina Aurobindo in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

Q: How do I order Ivabradina Aurobindo from GNH India?

To request Ivabradina Aurobindo, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Ivabradina Aurobindo compare with beta‑blockers?

Both Ivabradina Aurobindo and beta‑blockers lower heart rate, but they act via different mechanisms. Ivabradine selectively inhibits the If current without affecting beta‑adrenergic receptors, preserving contractility and blood pressure. Beta‑blockers reduce heart rate and contractility through adrenergic blockade, which may be advantageous or limiting depending on the patient’s profile.

Q: What are the recommended storage conditions for Ivabradina Aurobindo?

Ivabradina Aurobindo tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Keep the product away from moisture, heat and direct sunlight to maintain stability throughout its shelf life.

Q: How is Ivabradina Aurobindo administered?

Ivabradina Aurobindo is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Dosing times are typically spaced evenly, often twice daily, but the exact schedule is set by the prescribing clinician.

Q: What are the most serious risks associated with Ivabradina Aurobindo?

The most serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, and heart‑block conduction disturbances. Patients should be monitored for signs of these events, especially during dose initiation or when combined with other heart‑rate‑lowering drugs.

Q: Who should not use Ivabradina Aurobindo?

Ivabradina Aurobindo is contraindicated in patients with acute decompensated heart failure, severe hepatic impairment, sick sinus syndrome, second‑ or third‑degree atrioventricular block, and in those who are already on strong CYP3A4 inhibitors without appropriate dose adjustment.

Ivabradine Hydrochloride, the active ingredient in Ivabradina Aurobindo, is an If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate in patients with chronic stable angina pectoris and heart failure with reduced ejection fraction.

GNH India supplies Ivabradina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Aurobindo Pharma (Italia) S.R.L.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradina Aurobindo acts on the cardiac If current to manage conditions where heart‑rate reduction is therapeutic.
Chronic stable angina pectoris: improves exercise tolerance and decreases frequency of angina episodes.
Heart failure with reduced ejection fraction: lowers heart rate and may improve functional status.
Ischemic heart disease: helps control heart rate to reduce myocardial oxygen demand.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, slowing depolarisation of pacemaker cells. This reduces spontaneous heart‑rate without affecting myocardial contractility, ventricular repolarisation, or blood pressure, thereby decreasing cardiac oxygen consumption while preserving cardiac output.

Side Effects

Adverse reactions have been reported with Ivabradina Aurobindo.

Common Side Effects

Visual disturbances (phosphenes or luminous phenomena)
Bradycardia (heart rate <50 bpm)
Headache
Dizziness
Fatigue
Blurred vision

Serious or Rare Side Effects

Severe bradycardia requiring medical intervention
Atrial fibrillation or other supraventricular arrhythmias
Symptomatic hypotension
Heart block or other conduction abnormalities

Precautions & Warnings

Use of Ivabradina Aurobindo requires careful clinical assessment.

Heart‑rate monitoring: check resting heart rate before initiation and periodically thereafter.
Severe hepatic impairment: avoid or use only with specialist guidance.
Sick sinus syndrome or atrioventricular block: contraindicated.
Concomitant bradycardic agents (e.g., beta‑blockers): dose adjustment may be needed.
Acute decompensated heart failure: do not initiate therapy.
Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Ivabradina Aurobindo may interact with several medicines.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may markedly increase plasma levels.
Co‑administration with other bradycardic agents (e.g., beta‑blockers, digoxin) – risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely)

Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin) – may raise concentrations.
Calcium‑channel blockers that are CYP3A4 substrates (e.g., diltiazem, verapamil) – may increase exposure.
Antihypertensive agents – may enhance hypotensive effect.

Frequently Asked Questions

Ivabradina Aurobindo is prescribed to lower heart rate in patients with chronic stable angina pectoris and in those with heart failure that has a reduced ejection fraction. By slowing the sinus node, it helps relieve angina symptoms and may improve functional capacity in heart‑failure patients.

Ivabradine Hydrochloride selectively blocks the funny (If) current in the sinoatrial node. This current normally drives spontaneous depolarisation of pacemaker cells. Inhibition slows the heart’s intrinsic pacing, producing a controlled reduction in heart rate without decreasing myocardial contractility or blood pressure.

The dose of Ivabradina Aurobindo is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerability. Dosage adjustments are made during treatment to achieve the target heart‑rate range while monitoring for adverse effects.

The safety of Ivabradina Aurobindo in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Ivabradina Aurobindo, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Ivabradina Aurobindo and beta‑blockers lower heart rate, but they act via different mechanisms. Ivabradine selectively inhibits the If current without affecting beta‑adrenergic receptors, preserving contractility and blood pressure. Beta‑blockers reduce heart rate and contractility through adrenergic blockade, which may be advantageous or limiting depending on the patient’s profile.

Ivabradina Aurobindo tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Keep the product away from moisture, heat and direct sunlight to maintain stability throughout its shelf life.

Ivabradina Aurobindo is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Dosing times are typically spaced evenly, often twice daily, but the exact schedule is set by the prescribing clinician.

The most serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, and heart‑block conduction disturbances. Patients should be monitored for signs of these events, especially during dose initiation or when combined with other heart‑rate‑lowering drugs.

Ivabradina Aurobindo is contraindicated in patients with acute decompensated heart failure, severe hepatic impairment, sick sinus syndrome, second‑ or third‑degree atrioventricular block, and in those who are already on strong CYP3A4 inhibitors without appropriate dose adjustment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.